期刊文献+

Wnt/β-catenin信号通路与癌症发生发展及其免疫治疗 被引量:9

The Role of Wnt/β-catenin Signaling Pathway in Carcinogenesis and Immunotherapy
原文传递
导出
摘要 经典的Wnt/β-catenin信号通路参与调控机体的多种生物学功能,包括干细胞自我更新,细胞的增殖、分化、凋亡以及胚胎早期发育和组织再生等,与癌症发生发展紧密相关。此外,该信号通路在胸腺T细胞的发育和分化过程中发挥重要作用,影响抗肿瘤免疫效应的多个环节。异常激活的Wnt/β-catenin信号通路可诱导恶性肿瘤的形成并介导肿瘤免疫逃逸。详细阐述了Wnt/β-catenin信号通路与癌症发生发展及抗肿瘤免疫治疗的相关性,讨论了靶向Wnt/β-catenin信号通路药物的临床研究进展及其应用于疾病治疗领域所要面临的挑战和局限性。 The classic Wnt/β-catenin signaling pathway is involved in regulating various biological functions including stem cell self-renewal,cell proliferation,differentiation,apoptosis,early embryonic development and tissue regeneration,and it is closely related to the occurrence and development of cancer.In addition,this signaling pathway plays an important role in the development and differentiation of thymic T cells,and affects many aspects of the anti-tumor immune effect.Abnormally activated Wnt/β-catenin signaling pathway can induce the formation of malignant tumors and mediate tumor immune escape.This review elaborated on the correlation of Wnt/β-catenin signaling pathway with cancer occurrence and development as well as anti-tumor immunotherapy,and discussed the research progress of drugs targeting Wnt/β-catenin signaling pathway,and the challenges and limitations of its clinical application.
作者 张慧 陈华宁 库德莱迪·库尔班 王松娜 刘嘉扬 赵缜 叶丽 ZHANG Hui;CHEN Hua-ning;KUDELAIDI Kuerban;WANG Song-na;LIU Jia-yang;ZHAO Zhen;YE Li(Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics,School of Pharmacy,Fudan University,Shanghai 201203,China;Clinical Laboratory,Minhang Hospital,Fudan University,Shanghai 201199,China)
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2022年第1期104-111,共8页 China Biotechnology
基金 上海市科委生物医药科技支撑专项(20S11901600、18431902800)资助项目
关键词 WNT/Β-CATENIN信号通路 癌症发生发展 抗肿瘤免疫治疗 免疫逃逸 Wnt/β-catenin signaling pathway Cancer occurrence and development Anti-tumor immunotherapy Immune escape
作者简介 通讯作者:叶丽,电子信箱:yelil@fudan.edu.cn;通讯作者:赵缜,电子信箱:fdmh_zz@fudan.edu.cn
  • 相关文献

参考文献2

二级参考文献78

  • 1Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma.Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1].
  • 2El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683].
  • 3Llovet JM, Bruix J. Molecular targeted therapies in hepatocellularcarcinoma. Hepatology 2008; 48: 1312-1327 [PMID: 18821591DOI: 10.1002/hep.22506].
  • 4Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, PortaC, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, BorbathI, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,Bruix J. Sorafenib in advanced hepatocellular carcinoma. N EnglJ Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857].
  • 5Kudo M. Current status of molecularly targeted therapy forhepatocellular carcinoma: clinical practice. Int J Clin Oncol 2010;15: 242-255 [PMID: 20509038 DOI: 10.1007/s10147-010-0089-y].
  • 6Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellulartumors. Oncogene 2006; 25: 3778-3786 [PMID: 16799619 DOI:10.1038/sj.onc.1209547].
  • 7Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liverregeneration and hepatocellular cancer: sorting the good from thebad. Semin Cancer Biol 2011; 21: 44-58 [PMID: 21182948 DOI:10.1016/j.semcancer.2010.12.010].
  • 8Clevers H, Nusse R. Wnt/兝-catenin signaling and disease. Cell 2012;149: 1192-1205 [PMID: 22682243 DOI: 10.1016/j.cell.2012.05.012].
  • 9Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling inhepatocellular carcinoma. Front Biosci 2006; 11: 1901-1915[PMID: 16368566].
  • 10Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wntsignaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24 [PMID:12781368].

共引文献66

同被引文献75

引证文献9

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部